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1. Introduction
  Coronary heart disease is caused by coronary atherosclerosis, 
which leads to the occurrence of coronary artery atherosclerotic 
disease; and further causes myocardial ischemia, angina and 
myocardial infarction. Coronary heart disease has become a serious 
hazard to human health diseases. In recent years, studies for 
prevention and significant treatment of coronary heart disease have 
been undertaken from an anatomic and biochemical level of depth 
to the cell molecular level[1-3]. During hematopoiesis, miRNAs is 
an important class of negative regulator, which may be obtained by 
complementary matching the 3’-UTR region of target gene mRNA; 
leading to the inhibition received target mRNA translation; and 
furthermore participate in regulation of blood cell development, 
differentiation and apoptosis, hormone secretion, as well as 
biological processes such as signal transduction. Studies have 
Objective: To study the expression of miR-126 and miR-223 in platelet of rabbit arterial 
plaque models, and explore its correlation with plaque morphology. Methods: Rabbit arterial 
plaque models were established, peripheral blood of models and control animals was collected. 
Plaque morphologies were divided into type 栺, type 栻 and type 栿 based on angiography 
plaque morphology and Ambrose method. Platelet isolation kit was applied to isolate and 
purify peripheral blood platelets, CD45 immunomagnetic beads were used to remove the 
residual white blood cells. The miRNAs of platelets was extracted by miRNA Isolation Kit, 
and expressions of miR-126 and miR-223 of the platelets samples were detected by Real-time 
PCR. The correlation between plaque morphology and platelet-associated miR-126 and miR-
223 expressions were analyzed. Expressions of target gene VCAM-1 and P2Y12 receptors of 
miR-126 and miR-223 in the atherosclerosis plaque of rabbit model were detected by Western 
blot. Results: Relative expression levels of miR-126 and miR-223 in the model group were 0.27
依0.10 and 0.71依0.14, respectively. Plaque morphology was divided into types 栺, 栻 and 栿; 
and miR-126 and miR-223 expression levels were detected in each type. Expression levels of 
miR-126 in each type were 0.42依0.07, 0.17依0.11 and 0.22依0.15, respectively; and expression 
levels of miR-223 in each type are 0.68依0.02, 0.57依0.06 and 0.88依0.10, respectively. Relative 
to the control group, miR-126 and miR-223 known target genes in VCAM-1 and P2Y12 
receptors increased platelets in rabbit atherosclerotic plaque models (P<0.05). Conclusions: 
Relative to normal control animals, miR-126 and miR-223 platelets were reduced in the rabbit 
atherosclerotic plaque model group (P<0.05). In the type 栻 plaque morphology group, miR-
126 was greatly reduced; and there is no significant correlation between miR-223 and plaque 
morphology.
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shown that thousands of human protein-coding genes are performed 
by miRNA regulation, demonstrating that miRNAs plays various 
important roles in cell growth and regulation during the development 
process[4,5].
  Latest studies have shown that a number of miRNA expressions 
participated in regulating related gene expressions in platelets[6,7], 
and that platelets is an important factor in coronary heart disease 
and its development process. Therefore, studies conducted on 
platelet-associated miRNA expressions and their target gene 
regulatory process have important significance for understanding the 
involvement of platelets in relevant cardiovascular disease processes 
at the molecular level.
  With vascular function, miR-126 and miR-223 are closely related 
miRNAs[8,9], which could express in vascular endothelial cells 
and platelets. There is a direct relationship between the abnormal 
expressions of numbers of related vascular cell proteins with the 
occurrence of atherosclerosis. Further, miRNA expressions may 
be different between different types of atherosclerotic plaque 
morphologies. 
  In this study, a rabbit atherosclerotic plaque model was established 
to investigate the relevance of platelet-associated miR-126 and miR-
223 expressions with atherosclerotic plaque morphology; further 
understanding and providing some ideas on the role of miRNAs in 
the development of coronary artery diseases.
2. Materials and methods
2.1. Establishment of animal model
  One hundred, healthy, adult, male New Zealand white rabbits 
purchased from Shanghai SLRC Laboratory animals Co., weighing 
2.0-2.5 kg. Rabbits were randomly divided into two groups: 80 are 
for the atherosclerotic plaque group and 20 for the control group. 
Animals were fed and were allowed to freely consume water 
(high fat diet group); they were kept in standard animal cages 
with ventilation, natural day and night lighting, and a maintained 
temperature at 18-25 曟. 
2.2. Drug reagents and equipment
  Maverick 2 balloon (Boston-38928-0920); Platelet pure separation 
kit (ShangHai HaLin g Biological Technology Co.Ltd. -HL10366.2); 
Dynabeads CD45 (lifetechnologies-11153D); miRNA Isolation 
Kit(mirVana-AM1560); miRNA Reverse Transcription Kit (TaqMan-
4366596); Bulge-LoopmiRNA qRT-PCR Primer Set (Guangzhou 
RiboBio Co., Ltd.); Real-time PCR Fluorescence Quantitative 
Diagnosis Kits (SsoAdvanced SYBR Green Supermix, Bio-Rad-
172-5264); ReadyPrep Protein Extraction Kits (Bio-Rad); P2Y12 
antibody(Santa Cruz Biotechnology-sc27152); VCAM-1antibody 
(Santa Cruz Biotechnology-sc1504); Horseradish peroxidase (HRP) 
labeled secondary antibody (Wuhan Boster Biological Technology 
Co., Ltd.); ECL Color Development Kit (Millpore); PVDF 
Membrane (Polyvinylidene fluoride-Millpore); Color Doppler 
Ultrasonic Diagnosis Apparatus (Philips IU Elite); MultiSkan FC 
enzyme mark instrument  (Thermo Scientific); Fluorescence RT-
PCR detect system CFX96 Touch (Bio-Rad).
2.3. Establishing the animal model
  The rabbit model commenced after one week in adaptive feeding. 
Control animals were fed with a normal diet, while model animals 
were fed with a high fat diet (containing 2% cholesterol). Animals 
were fed according to a 150 g/day amount of feeding, continuously 
fed for eight weeks, and lipids were measured to determine high 
cholesterol formation. The rabbits were anaesthetized with 3% 
sodium pentobarbital by intravenous infusion. The balloons were 
inserted through the external carotid artery to induce intimal injury. 
Antibiotic was administered intramucularly to prevent postoperative 
infection, then continued to fed for 4 weeks; Philips IU Elite color 
Doppler ultrasound was used to examine the left and right carotid 
arteries. Transverse scans were conducted along the vessel, so as to 
observe whether there is intimal thickening and the size of plaque 
and characteristics of echo. Puncture needles were introduced 
percutaneously into the femoral artery or radial artery, a special 
catheter was sent along the descending aorta retrograde to the aortic 
root, and the catheter was placed in the left and right coronary 
ostia, respectively. Then, Iopromide was injected and X-ray video 
was turned on at the same time. There are 74 cases of coronary 
angiography for atherosclerosis or vascular blockage for the study. 
According to the Ambrose aliquot type method[10,11], plaques were 
divided into three types according to morphological expressions: 
type 栺, concentric or eccentric plaques with smooth surface and 
plaque with a wide base; type 栻, plaque has a narrow base or cusp-
shaped (both surface smooth or matte), plaque surface have shadow 
niches, plaque surface uneven, or were wavy or crater-like (radial or 
bias); type 栿, long segments of irregularly narrow plaques.
2.4. Platelet isolation and purification
  Venous blood containing anticoagulants were collected in blood 
collection tubes; and stored at room temperature after obtaining 
platelets by centrifugation, according to high purity platelet isolation 
kit instructions. Dynabeads CD45 MACS kit was used to purify 
peripheral blood platelets according to manufacturer’s instructions; 
precipitation was obtain after removal of platelet leukocytes.
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2.5. Expressions of miR-126 and miR-223 by Real-time 
PCR
  Platelet total miRNA was extracted by miRNA Isolation Kit 
and stored at -80 曟. RNA solution A260 was detected by UV 
spectrophotometer and RNA concentration was calculated, RNA 
purity was evaluated by OD260 /OD280 ratio. According to the TaqMan 
miRNA Reverse Transcription Kit, miRNA-specific primers were 
used to conduct reverse transcription. Reverse transcription was only 
conducted to mature miRNA instead of pre-mirna, and its transcript 
CDNA was used as a template. Expressions of miR-126 and miR-
223 were detected by Real-time PCR. 2-△ Ct value method was used 
to calculate relative expression levels of target genes, average of 
three replicate experiments was the Ct value for each sample, △Ct 
=Ct(Target gene)-Ct(internal reference ), △△Ct= △Ct(sample) 
-△Ct (contro1), so relative expression levels of target gene = 
2- △△ Ct, relative expression of the control group is 20 = 1, reference 
gene is U6.miR-126, miR-223 and U6-specific primers were all 
purchased from Guangzhou Ribobio company. CFX Manager 
software was used to analyze Real-time PCR results. PCR reaction 
system is showed in Table 1. 
Table 1
PCR reaction system.
Components Volume per reaction
SsoAdvanced SYBR Green
Super mix 5 毺L
Forward primer (10 毺M) 0.35 毺L (350 nM)
Reverse primer (10 毺M) 0.35 毺L (350 nM)
cDNA template 100 ng
Nuclease-free water Up to 10 毺L
SsoAdvanced SYBR Green Super mix, purchased from Bio-Rad.
2.6. Western blot
  Platelet samples were collected and washed two times with PBS. 
Cells were filtered with 1 mL pipette, and the supernatant was 
removed by centrifugation. Platelet precipitation was lysed by 
ReadyPrep protein extraction kit lysate, then protease inhibitor 
cocktail was added, mixed by pipetting. After the samples were 
placed on ice for 30 minutes, cells were lysed by ultrasonic waves. 
The lysed mixture was placed at 4 曟 and centrifuged at 13 000 r/
min for 20 minutes; protein concentrations in the new supernatant 
were determined using a Protein Assay Kit. Protein samples 
extraction was performed by SDS-PAGE electrophoresis. The gel 
was immersed into transfer buffer equilibrium for 10 minutes, and 
plugged the electrode at 100 V for 45-60 minutes. After the film 
was transferred, PVDF membrane was rinsed with TBS for 10-15 
minutes. The film was placed in a TBS/T blocking buffer containing 
5% (w/v) skimmed milk powder, shaking for one hour at room 
temperature, appropriate dilution of primary antibody [containing 
1% (w/v) skimmed milk powder in TBS/T dilution] was added, 
incubated at room temperature for two hours, and TBST rinsed the 
membrane three times every 5-10 minutes. The film was incubated 
in a TBST diluted secondary antibody (1:10 000, HRP labeled) 
containing 0.05% (w/v) nonfat dry milk at room temperature for 
one hour. TBS/T rinsed the film three times every 5-10 minutes, 
exposed, took a photo, and experiment results were saved. Repeated 
experiment for three times. Quantity one v4.62 software molecular 
bands were used for gray value (Trace Tracking), drawing the optical 
density curve according to different subunit bands. Areas under the 
optical density curves were calculated as a quantity reference for 
electrophoretic bands and results were statistically analyzed.
2.7.  Statistical analysis
  SPSS 17.0 statistical software was applied to the experimental data, 
and results were expressed as mean依SD. t-test was used to compare 
test the two groups. P<0.05 was considered statistically significant.
3. Result
3.1. Expressions of miR-126 and miR-223 in platelet 
samples were detected by real-time PCR
  A total of 74 rabbits atherosclerotic plaque model were successfully 
established and 20 rabbits were used as healthy controls. Platelets 
were obtained after isolation and purification of peripherals. Total 
miRNAs was extracted by kit, and then reverse transcribed into 
cDNA. Expressions of miR-126 and miR-223 were detected by 
Real-time PCR. Figure 1 is PCR reaction amplification curve 
(Amplification curve of control group and model group, miR-126 
group and miR-223 group respectively). The result was shown in 
Figure 2.
  Figure 3 showed the data distribution of miR-126 and miR-223 in 
three kinds of plaque morphology, and correlation between plaque 
morphology and miR-126 and miR-223 expressions. That is,miR-
126 expression is the lowest in Type 栻 plaque morphology group; 
however, miR-126 expression is evenly distributed in type 栺 plaque 
morphology group, there is no significant correlation, and there 
is no significant correlation between miR-223 and three plaque 
morphology. A, Relative expression of miR-126 and miR-223 (2- △△ Ct
method),wherein relative expression levels of miR-126 and miR-
223 in the model group were 0.27依0.1 and 0.71依0.14, respectively. 
B-C. Plaque morphology was divided into types 栺, 栻 and III; and 
miR-126 and miR-223 expression levels were detected in each type. 
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Expression levels of miR-126 in each type are 0.42依0.07, 0.17依
0.11 and 0.22依0.15, respectively; and expression levels of miR-223 
in each type are 0.68依0.02, 0.57依0.06 and 0.88依0.10, respectively. 
D, Detected the internal reference U6 expression in samples of each 
group.
 







































































Figure 2. Real-time PCR to detect expressions of miR-126 and miR-223 in 
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Figure 3. Data distribution of miR-126 and miR-223 in three kinds of plaque 
morphology.
3.2. Detection of VCAM-1 and P2Y12 receptors in the plaque 
by Western blotting
  Total protein of platelet samples in each group was extracted by 
kit,and expressions of target gene VCAM-1 and P2Y12 receptors of 
miR-126 and miR-223 were detected by Western blot. As shown in 
figure 3, the VCAM-1 and P2Y12 receptors in the healthy control 
group were in a low level, however,the results showed that VCAM-1 
and P2Y12 receptors in platelets were significantly increase in the 
model group (P<0.05). Table 2 is analysis of relative signal value 
of the target protein through protein bands signal value of internal 
reference by Quantity one software. 





Figure 4. VCAM-1 and P2Y12 receptors in the plaque by Western blotting.
Table 2 
Analysis of relative signal value by Quantity one software . 





Type栺 Type栻 Type 栿
VCAM-1 0.32 0.92* 0.96* 1.04**
P2Y12 0.24 1.33* 1.18* 1.09*
*P<0.05, **P<0.01.
4. Discussion
  Coronary heart disease is caused by coronary atherosclerosis, which 
leads to the occurrence of coronary artery atherosclerosis; and further 
cause myocardial ischemia, angina and myocardial infarction. The 
pathogenesis of coronary heart disease remains unclear; thus, there 
is a lack of effective treatment. Thrombosis is an important incentive 
for cardiovascular disease, which is currently widely accepted in 
cardiovascular research[12,13]. With the in-depth study of thrombosis, 
the role played by thrombosis in platelets would be clearer. A 
reliable animal model of atherosclerosis has important significance 
to ascertain the pathogenesis of atherosclerosis and for the research 
and development of prevention and treatment drugs. Rabbits are 
herbivores; and under normal conditions, high cholesterol rarely 
occurs. In this study, high-fat diet caused high cholesterol. To 
establish a rabbit atherosclerotic plaque model, a balloon was used 
and inserted into the artery. This caused intimal tear during the 
experiment. Postoperative infection is the main reason for the failure 
of this model. Some animals also failed to induce plaque formation.
  miRNAs are short and small non-coding RNA molecules that 
are similar to highly conservative siRNA molecules. miRNAs 
are equivalent 20-25 nucleotides in length and regulate post-
transcriptional mRNA expressions, which are usually complementary 
to miRNAs binding sequence in the 3 ‘untranslated region (3’-UTR); 
and leads to silence suppression and gene conversion. Studies have 
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shown that thousands of human protein-coding genes are carried out 
by miRNA regulation, indicating that miRNAs plays an important 
role in a variety of processes in cell growth and development. As 
miRNAs research techniques continues to develop, platelet miRNA, 
as the central gene expression regulatory mechanism, has presently 
become a focus in cardiovascular disease[14-16]. Platelets are 
released into the peripheral circulation of blood, after bone marrow 
megakaryocyte shedding. Their seedless characteristics determine 
the synthesis and mechanism of action of platelet miRNAs, which 
may differ from the regulatory mechanisms of miRNAs in nucleated 
cells. The study shows that miRNAs is indeed involved in regulating 
expressions in a number of genes in platelets; therefore, we believe 
platelets miRNAs can be used as a cardiovascular disease platelet 
activation level for monitoring, diagnosis, prognosis and efficacy 
evaluation index, while clinical gene therapy for thrombotic diseases 
is also possible.
  According to the classification method of Ambrose et al[10,11], 
these were divided into three types according to plaque morphology 
performance. Platelet samples were isolated by platelets isolation kit 
and residual leukocytes were removed using CD45 magnetic beads 
to purify the platelets. Total miRNAs were extracted from platelet 
samples and reverse transcribed into cDNA. Expression levels of 
miR-126 and miR-223 in platelets were detected by real-time PCR. 
From the results, we found that miR-126 in animal platelets of the 
model group significantly reduced (P<0.01) and miR-223 has also 
shown a downward trend (P<0.05); suggesting that the abnormal 
expression of miR-126 and miR-223 can be related to the occurrence 
of atherosclerotic plaques. Thus, we also further detected VCAM-1 
and P2Y12 receptors in miR-126 and miR-223 known target genes 
by Western blotting. The results showed that VCAM-1 and P2Y12 
receptors in platelets had different degrees of increase in the model 
group. The negative correlation in Real-time PCR results prompted 
the low expressions of miR-126 and miR-223; and raised the 
target gene expressions of VCAM-1 and P2Y12 in platelets; thus, 
exerting its biological effects. Although the regulatory processes of 
miRNAs are complex, same miRNAs may regulate the expression of 
multiple genes; simultaneously, a gene is often regulated by multiple 
miRNAs[17]. However, VCAM-1 and P2Y12 genes in platelets in the 
animal model group significantly increase, which may be caused by 
the abnormal expressions of miR-126 and miR-223. Using simulated 
endogenous miRNAs: miRNA mimic, and miRNAs inhibitors: to 
have a clearer understanding of miRNA inhibitors in regulating miR-
126 and miR-223 in platelets; this would be the focus of our future 
research. 
  In order to investigate the correlation of miR-126 and miR-223 
expression levels with plaque morphology, we grouped platelet 
samples according to different plaque morphology and detected 
the expressions of miR-126 and miR-223. From the results, we can 
conclude that miR-126 was underexpressed in platelets in the model 
group; and their expressions were not the same in different plaque 
morphologies. Type 栻 had the lowest (P<0.01), type 栺 had the 
highest (P<0.05) and type 栿 had intermediate expression levels of 
miR-126 in the different plaque morphology groups. This may be 
related to the miR-126 regulation of vascular endothelial growth 
factor (VEGF) expression[18,19]. VEGF can nourish atherosclerotic 
plaques proliferation during blood vessel growth; thus, miR-126 has 
a certain correlation with coronary stenosis. In this study, miR-126 
target gene VCAM-1 was detected by triggering local immunity and 
release of various cytokines; thus, promoting the formation of early 
atherosclerotic plaques[20]. In the type 栿 plaque morphology group, 
miR-223 expressed in higher; and the remaining difference between 
the two groups were not significant. As one of their target genes in 
P2Y12 platelets, ADP receptor is a central regulating terminal of 
platelet activation control[21]. Thus, the abnormal expression of miR-
223 was the same in platelets in the model group; suggesting that 
this plays an important role in the occurrence and development of 
atherosclerotic plaque formations.
  With platelet miRNAs findings and their regulatory mechanisms 
of gene expression revealed, further studies on platelet effects on 
cardiovascular disease provides new ideas; and also for building a 
new platform for platelet internal molecular mechanisms. Identifying 
the important functions platelet miRNAs and function of its target 
genes would become an important research direction in platelet 
research.
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